BIND Therapeutics Co-Founders Demonstrate Ability to Cross Biological Barriers with Targeted Therapeutic Nanoparticles
(Nanowerk News) BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, announced today that the company’s co-founders have published data demonstrating the successful engineering of targeted nanoparticles to cross biological barriers, such as the intestinal barrier, and enter the bloodstream, potentially broadening future therapeutic applications for BIND’s Medicinal Nanoengineering platform.
In a paper entitled, "Transepithelial Transport of Fc-Targeted Nanoparticles by the Neonatal Fc Receptor for Oral Delivery”, published in the November 27, 2013 online issue of Science Translational Medicine, researchers at the Massachusetts Institute of Technology David Koch Institute for Integrative Cancer Research and Brigham and Women’s Hospital/Harvard Medical School, including BIND’s co-founders Robert Langer Sc.D., and Omid Farokhzad, M.D., demonstrated the ability to enhance the surface properties of the nanoparticle to target the neonatal Fc receptor (FcRn), a transport receptor present on the plasma membrane of cells that form many of the biological barriers in the body including: intestinal epithelial barrier, pulmonary epithelial barrier, blood-brain barrier, fetal-placental barrier, and blood-ocular barrier. The FcRn function is to shuttle Immunoglobulin G (IgG) molecules across biological barriers that are otherwise impermeable to IgG. Taking advantage of the biological properties of the FcRn as a model transcellular trafficking receptor, the investigators demonstrated for the first time, proof of concept in a preclinical model that targeted therapeutic nanoparticles can exploit biological transport pathways and gain access to biological compartments that are otherwise impermeable to nanoparticles and other macromolecules. The FcRn-targeted nanoparticles were shown in an animal model to cross the intestinal epithelial barrier after oral administration and enter the systemic circulation, displaying an absorption efficiency that enabled uptake of therapeutic dose levels. As expected, the FcRn-mediated nanoparticle absorption was lost in animals deficient in FcRn expression. Using insulin as a model large molecular weight drug with minimal oral bioavailability, the FcRn-targeted nanoparticles were able to significantly increase insulin bioavailability resulting in plasma glucose modulation.
“BIND has used its Medicinal Nanoengineering platform to produce a pipeline of Accurins, including its proprietary lead drug candidate, BIND-014, currently in Phase 2 clinical trials in non-small cell lung cancer and metastatic castrate-resistant prostate cancer, and partnered Accurins through our collaborations initiated in 2013 with Amgen, Pfizer and AstraZeneca,” said Scott Minick, BIND’s President and Chief Executive Officer. “The current findings are expected to significantly broaden the reach of our platform and present opportunities to non-invasively administer Accurins of large molecular weight drugs, such as proteins and RNA, for a myriad of human diseases.”
“Up to this point, biological barriers present in the human body, such as the intestinal epithelial lining, the blood brain barrier, and the mucosa of the lungs and eyes, have hindered absorption of nanoparticles. By targeting the neonatal Fc receptor, our founders have demonstrated the ability to successfully engineer targeted therapeutic nanoparticles that cross biological barriers and enter the bloodstream at therapeutic levels, which we believe could pave the road for opportunities for Accurin therapeutics for a myriad of other biological applications,” said Jeff Hrkach, Ph.D., BIND’s Senior Vice President of Technology, Research and Development.
About BIND Therapeutics
BIND Therapeutics is a clinical-stage nanomedicine platform company developing Accurins, its novel targeted therapeutics. BIND intends to leverage its Medicinal Nanoengineering platform to develop a pipeline of Accurins, initially in oncology, as well as Accurins in collaboration with biopharmaceutical companies. BIND’s lead drug candidate, BIND-014, is an Accurin that targets PSMA and contains docetaxel, a clinically-validated and widely used cancer chemotherapy drug. BIND-014 is currently in Phase 2 clinical trials for non-small cell lung cancer and metastatic castrate-resistant prostate cancer. To date in 2013, BIND has announced collaborations with Amgen, Inc., Pfizer Inc. and AstraZeneca AB to develop Accurins based on therapeutic payloads from their product pipelines. BIND’s platform originated from the pioneering nanotechnology research at the Massachusetts Institute of Technology and Brigham and Women’s Hospital/Harvard Medical School of BIND’s scientific founders and directors Dr. Robert Langer and Dr. Omid Farokhzad. For more information, please visit the company's web site at www.bindtherapeutics.com.
Source: BIND Therapeutics (press release)
If you liked this article, please give it a quick review on reddit or StumbleUpon. Thanks!
Check out these other trending stories on Nanowerk: